Zhejiang Orient Gene Biotech Past Earnings Performance
Past criteria checks 0/6
Zhejiang Orient Gene Biotech's earnings have been declining at an average annual rate of -13.4%, while the Biotechs industry saw earnings growing at 3.1% annually. Revenues have been growing at an average rate of 5.5% per year.
Key information
-13.4%
Earnings growth rate
-13.9%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 5.5% |
| Return on equity | -8.6% |
| Net Margin | -79.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Zhejiang Orient Gene Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 737 | -584 | 613 | 283 |
| 31 Mar 24 | 627 | -415 | 576 | 281 |
| 31 Dec 23 | 820 | -398 | 565 | 261 |
| 30 Sep 23 | 1,562 | -1,056 | 478 | 299 |
| 30 Jun 23 | 2,158 | -639 | 415 | 288 |
| 31 Mar 23 | 4,398 | -49 | 504 | 458 |
| 31 Dec 22 | 8,768 | 2,068 | 749 | 512 |
| 30 Sep 22 | 10,626 | 4,052 | 1,063 | 586 |
| 30 Jun 22 | 10,898 | 4,268 | 975 | 580 |
| 31 Mar 22 | 12,680 | 5,801 | 1,235 | 510 |
| 31 Dec 21 | 10,169 | 4,920 | 1,166 | 429 |
| 30 Sep 21 | 9,565 | 4,932 | 1,044 | 295 |
| 30 Jun 21 | 8,819 | 4,548 | 1,086 | 263 |
| 31 Mar 21 | 5,391 | 2,820 | 669 | 109 |
| 31 Dec 20 | 3,265 | 1,677 | 386 | 94 |
| 30 Sep 20 | 1,206 | 688 | 98 | 50 |
| 30 Jun 20 | 1,026 | 573 | 85 | 43 |
| 31 Mar 20 | 398 | 114 | 54 | 33 |
| 31 Dec 19 | 367 | 82 | 54 | 32 |
| 30 Sep 19 | 343 | 76 | 51 | 28 |
| 31 Dec 18 | 286 | 65 | 46 | 19 |
| 31 Dec 17 | 224 | 33 | 43 | 12 |
| 31 Dec 16 | 182 | 36 | 34 | 9 |
Quality Earnings: 688298 is currently unprofitable.
Growing Profit Margin: 688298 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688298 is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.
Accelerating Growth: Unable to compare 688298's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688298 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (10.1%).
Return on Equity
High ROE: 688298 has a negative Return on Equity (-8.57%), as it is currently unprofitable.